Targeting wild type NTRK decreases brain metastases of lung cancers non-driven by NTRK fusions

This study demonstrates that FDA-approved NTRK inhibitors like entrectinib can effectively prevent and reduce brain metastases in lung cancers lacking NTRK fusions by blocking wild-type NTRK2 signaling activated by brain-derived neurotrophic factor (BDNF) within the central nervous system niche.

The Gist

The Big Picture: A "Brain-Only" Problem

Imagine lung cancer cells as unwanted tenants trying to move into a new city. For many patients, the most dangerous "neighborhood" they try to invade is the Brain.

Once these cancer cells get into the brain, they are incredibly hard to kick out. Current treatments (like targeted drugs) work great, but only if the cancer has a specific "key" (a genetic mutation) that the drug can lock onto. Unfortunately, most lung cancers don't have this specific key. They are "wild type," meaning they look normal in the genetic sense, so doctors can't use the powerful "master keys" (like Entrectinib) to stop them.

The Problem: We have a powerful drug (Entrectinib) that can penetrate the brain and stop cancer, but we thought it only worked on cancers with specific mutations. This study asks: Can this drug stop lung cancer in the brain even if the cancer doesn't have that specific mutation?

The Discovery: The Cancer's "Secret Handshake"

The researchers discovered that even without the specific genetic mutation, lung cancer cells still have a "backdoor" into the brain.

1. The Lock (TrkB): The cancer cells have a receptor on their surface called TrkB. Think of this as a door handle.
2. The Key (BDNF): Inside the brain, there are helper cells called astrocytes (the brain's support staff). These astrocytes are constantly releasing a protein called BDNF. Think of BDNF as a golden key that fits perfectly into the TrkB door handle.
3. The Party: When the cancer cells enter the brain, the astrocytes hand them this golden key. The cancer cells use it to unlock their own growth engines. They start multiplying rapidly, ignoring the body's defenses.

The study found that this "handshake" happens in many lung cancer patients, even those without the rare genetic mutations we usually look for.

The Solution: The "Universal Locksmith"

The researchers tested a drug called Entrectinib.

• How it works: Imagine Entrectinib as a super-strong glue or a jamming device. It doesn't just block the specific "master key" mutation; it jams the TrkB door handle itself.
• The Result: Even though the cancer cells are holding the golden key (BDNF) from the brain's astrocytes, the door handle (TrkB) is jammed. The cancer cells can't turn the key. They can't grow. They can't survive.

The Experiments: What They Found

The team did three main things to prove this:

1. In the Lab (The Petri Dish):
   They grew lung cancer cells with brain cells (astrocytes). The cancer cells grew like weeds. But when they added Entrectinib, the weeds stopped growing. It was like pouring a herbicide that only works on the specific "brain-weeds."

2. In Mice (The Prevention Test):
   They injected cancer cells into mice and gave some mice the drug before the cancer could even settle in.

   • Result: The mice treated with the drug had almost zero brain metastases. The drug stopped the cancer from ever getting a foothold in the brain.
   • Bonus: The drug didn't really stop the cancer in the lungs or liver. This is huge because it suggests the drug is specifically targeting the brain environment (the BDNF keys), not just killing the cancer everywhere indiscriminately.

3. In Mice (The Treatment Test):
   They let the cancer grow in the brain first, then started the drug.

   • Result: The drug slowed down the growth of existing brain tumors significantly. It shrank the tumors and stopped them from getting bigger.

Why This Matters (The "So What?")

Currently, if a patient has lung cancer that spreads to the brain but doesn't have the rare NTRK mutation, doctors often run out of good options.

This study suggests a new strategy: We don't need to wait for the cancer to mutate. We can look for patients whose cancer cells have the "TrkB door handle" (which many do) and give them Entrectinib.

• The Analogy: Think of the brain as a fortress. The cancer tries to sneak in. The brain's own support staff (astrocytes) accidentally gives the intruders a master key (BDNF) to open the gates. This study shows that if we use a drug that jams the lock (Entrectinib), we can stop the intruders, even if they didn't bring their own special key.

The Bottom Line

This research offers hope. It suggests that a drug already approved by the FDA (Entrectinib) could be used to prevent or treat brain metastases in a much wider group of lung cancer patients than we thought possible. It turns a "brain-specific" weakness of the cancer into a target we can hit, potentially saving lives by keeping cancer out of the most critical organ.

Technical Summary

1. Problem Statement

Brain metastases (BM) are a leading cause of mortality in lung cancer patients, affecting 20–56% of those with advanced disease. While tyrosine kinase inhibitors (TKIs) have improved outcomes for patients with specific oncogenic drivers (e.g., EGFR, ALK, ROS1), therapeutic options for preventing or treating brain metastases in tumors lacking these specific drivers remain limited.

A critical gap exists regarding the role of wild-type (WT) NTRK receptors (specifically TrkB/NTRK2) in non-fusion lung cancers. Although NTRK inhibitors (like entrectinib) are FDA-approved for NTRK-fusion-positive tumors, their efficacy in NTRK-fusion-negative tumors is unclear. The authors hypothesize that the brain microenvironment, rich in the ligand Brain-Derived Neurotrophic Factor (BDNF), can activate WT-TrkB receptors on lung cancer cells via paracrine signaling (from astrocytes and neurons), driving metastatic colonization and progression independent of gene fusions.

2. Methodology

The study employed a multi-faceted approach combining bioinformatics, in vitro cell biology, and in vivo preclinical models:

• Bioinformatics & Clinical Samples:
  • Analyzed TCGA-LUAD data for NTRK1/2/3 mRNA expression in primary lung adenocarcinomas.
  • Used spatial transcriptomics (GSE200563) to compare NTRK expression between matched primary tumors and brain metastases.
  • Performed Immunohistochemistry (IHC) on archival human lung cancer brain metastasis samples (n=9) lacking NTRK fusions to confirm TrkB protein expression.
• Cell Lines:
  • Utilized human and murine NSCLC cell lines with various drivers (KRAS, EGFR, ALK) but no NTRK fusions: LU65, H358, PC9Br3 (brain-tropic), H2030Br3 (brain-tropic), and CMT167.
  • Used primary neonatal mouse astrocytes to generate conditioned media (Ast-CM) and for co-culture experiments.
• In Vitro Assays:
  • Signaling: Western blotting to assess phosphorylation of TrkB, AKT, and ERK following stimulation with exogenous BDNF or Ast-CM.
  • Proliferation: Live-cell imaging (IncuCyte) to measure confluence/growth under treatment with TKIs (Entrectinib, LOXO-101, Cyclotraxin, ANA-12) with or without BDNF/Ast-CM.
  • Co-culture: GFP-labeled cancer cells plated on monolayers of primary astrocytes to mimic direct cell-cell contact.
• In Vivo Models (NSG Mice):
  • Preventive Study: Female NSG mice received Entrectinib (60 mg/kg, BID) starting 3 days before intracardiac injection of H2030Br3-GFPLuc cells.
  • Therapeutic Study: Mice were injected intracardially; treatment began only after established brain metastases were detected via IVIS (approx. 3 weeks post-injection).
  • Readouts: Longitudinal IVIS imaging (head vs. extracranial flux), ex vivo organ imaging, and histological quantification of micro- and macro-metastases.

3. Key Contributions

• Mechanistic Insight: Demonstrated that WT-TrkB is expressed in primary lung tumors and brain metastases, and its activation is driven by the brain microenvironment (specifically BDNF secreted by astrocytes) rather than gene fusions.
• Drug Repurposing: Provided preclinical evidence that Entrectinib, an FDA-approved pan-TRK inhibitor, can effectively block WT-TrkB signaling and brain metastatic progression in NTRK-fusion-negative lung cancers.
• Microenvironment Dependency: Highlighted that the efficacy of TRK inhibition is context-dependent; while Entrectinib blocks proliferation in isolation, the brain microenvironment (astrocytes) provides robust survival signals that can partially rescue cancer cells, yet Entrectinib remains effective in reducing overall burden.
• Organ-Specificity: Showed that the therapeutic effect is specific to the brain (and to a lesser extent the liver), with minimal impact on extracranial (lung) metastases, suggesting a paracrine mechanism dependent on organ-specific ligand availability.

4. Key Results

A. Expression and Activation of WT-TrkB

• Expression: NTRK2 (TrkB) mRNA is highly expressed in lung adenocarcinomas and remains stable in matched brain metastases. TrkB protein is confirmed in human BM samples and various NSCLC cell lines.
• Activation: Exogenous BDNF and Astrocyte-Conditioned Media (Ast-CM) robustly activate TrkB, leading to downstream phosphorylation of AKT and ERK within 5–10 minutes.
• Autocrine/Paracrine: Some cell lines (e.g., PC9Br3) show constitutive activation due to endogenous BDNF, while others rely on paracrine signals from astrocytes.

B. In Vitro Efficacy of Entrectinib

• Signaling Blockade: Entrectinib (1 µM) effectively blocked BDNF-induced and Ast-CM-induced AKT/ERK phosphorylation in multiple cell lines (H358, H2030Br3, CMT167). It was superior to other inhibitors (LOXO-101, Cyclotraxin, ANA-12) in this context.
• Proliferation: Entrectinib significantly reduced cell proliferation in the presence of BDNF and Ast-CM.
• Co-culture: In astrocyte co-cultures, Entrectinib significantly reduced proliferation in H2030Br3, LU65, and PC9Br3 cells. However, H358 cells became resistant to Entrectinib when in direct contact with astrocytes, suggesting alternative survival pathways exist in the tumor microenvironment.

C. In Vivo Efficacy (Brain Metastasis)

• Prevention: In the preventive model, Entrectinib treatment significantly reduced brain metastatic colonization (lower head IVIS flux, fewer micro- and macro-metastases on histology) compared to vehicle.
• Therapeutic: In the therapeutic model (established BMs), Entrectinib slowed the progression of brain metastases.
• Selectivity: Crucially, Entrectinib had no significant effect on extracranial metastatic burden (lungs) and only a moderate effect on the liver. This confirms that the anti-metastatic effect is driven by the high BDNF levels in the brain/liver niche activating WT-TrkB, rather than a general cytotoxic effect on the tumor cells.
• Target Inhibition: Immunofluorescence of brain sections showed significantly reduced p-TrkB intensity in Entrectinib-treated mice compared to vehicle controls.

5. Significance and Conclusion

This study provides a strong preclinical rationale for expanding the use of FDA-approved NTRK inhibitors (specifically Entrectinib) to patients with lung cancer who lack NTRK fusions but express wild-type TrkB.

• Clinical Implication: It suggests a shift in strategy from targeting only oncogenic drivers to targeting microenvironment-dependent survival pathways. Since the brain is a "hotspot" for BDNF, blocking TrkB could serve as a prophylactic or therapeutic strategy to prevent CNS metastasis in high-risk lung cancer patients.
• Mechanism: The findings underscore that brain metastasis is not solely a function of tumor genetics but is heavily influenced by the host microenvironment (astrocytes/neurons) via the BDNF-TrkB axis.
• Future Directions: The authors suggest that clinical trials should evaluate Entrectinib for the prevention of brain metastases in non-fusion lung cancers, potentially stratifying patients by TrkB expression levels. They also note the need to balance efficacy with potential side effects related to normal NTRK function in the brain (e.g., pain, memory).

In summary, the paper demonstrates that targeting wild-type NTRK receptors with brain-penetrant inhibitors can effectively disrupt the brain-specific survival niche of lung cancer cells, offering a novel avenue to combat brain metastases.